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Summary Cervical intraepithelial neoplasia (CIN) grades I to III lesions (n = 94) and squamous cell car-
cinomas of the uterine cervix (n = 27) were analysed for MHC class I and II expression and presence of HPV
genotypes.
MHC class I and II expression was studied by immunohistochemistry and HPV typing was performed by
general primer- and type-specific primer mediated PCR (GP/TS PCR). Both techniques were performed on
paraffin embedded tissue sections.
Results show disturbed MHC class I heavy chain expression in CIN I to CIN III, as well as in cervical
carcinomas. Upregulated MHC class II expression on dysplastic epithelial cells was also found in the different
CIN groups and carcinomas. Prevalence of HPV genotypes increased with the severity of the lesion, mainly
due to the contribution of the HPV types 16 and 18. No correlation could be established between the presence
of specific HPV genotypes and any MHC expression pattern in the different CIN groups or cervical
carcinomas. In some cases these data were confirmed by RNA in situ hybridisation showing HPV 16 E7
transcripts in the same dysplastic/neoplastic cells from which MHC status was determined. The results indicate
that local differences may exist in the type of cellular immune response to HPV induced lesions.
A central role in the antigen-specific immune response is
played by the major histocompatibility complex (MHC),
which are cell surface proteins that act as restricting elements
in the recognition of antigen by T-cells. MHC class I (MHC-
I) present endogenous antigen to cytotoxic T-lymphocytes
(CTLs). Low levels or lack of MHC-I surface expression can
consequently render aberrant cells non-immunogenic to
CTLs, and may provide a way for cells to escape immune
surveillance. MHC-1 alterations have been described in hu-
man cancer of different sites of the body (see review Ruiz-
Cabello et al., 1991).
Generally, MHC class II (MHC-II) surface expression is
restricted to specialised antigen presenting cells (APCs), that
present mainly opsonised exogenous antigen to T-helper cells.
Recognition leads to activated T-cells, which can stimulate
B-cell, CTL proliferation and MHC non-restricted killing by
natural killer (NK) cells or activated macrophages. Occas-
ionally, other cells like neoplastic epithelial cells have been
described to express MHC-II, which could assist in the onset
of the cellular immune response (Ostrand-Rosenberg et al.,
1991).
Infections with specific human papillomavirus (HPV) types
are strongly associated with the development of cervical
cancer, with HPV types 16 and 18 as the most predominant
types (Zur Hausen, 1989). This is supported by the increasing
prevalence of HPV 16/18 with increasing severity ofdysplasia
to cervical carcinoma (van den Brule et al., 1991; Lungu et
al., 1992) and the capacity of these viruses to transform in
vitro their natural host cells, the keratinocytes. These cells are
immortalised (Durst et al., 1987; Pirisi et al., 1987) and show
abnormal differentiation (McCance et al., 1988; Woodworth
et al., 1990), but are initially non-tumorigenic in animals.
This indicates that additional events besides infections with
high risk HPVs are involved in the pathogenesis of cervical
cancer. These events may include activation of cellular proto-
oncogenes, genetic inactivation of tumour suppressor genes,
HPV integration into the cellular genome and failure of
immune surveillance (Zur Hausen, 1989a). In accordance
with the last fact it has been shown recently that altered
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expression of MHC-I and -II is present in a substantial
number of HPV 16/18 DNA containing cervical carcinomas
(Connor & Stern, 1990; Glew et al., 1992), suggesting that
changes in the presentation of viral tumour antigens to the
cellular immune system can occur. However, to get insight
whether altered MHC-I and -II expression is related to the
development of cervical cancer from its premalignant lesions,
it is necessary to study dysplastic cervical lesions (CIN) for
the MHC-I and -II status.
Tumour virus based mechanisms have been described that
specifically influence MHC-I cell surface expression (Signas et
al., 1982; Schrier et al., 1983). Similar mechanisms could exist
for HPV affecting antigen presentation of the infected cells.
However, little is known about MHC alterations in CIN
lesions in relation to the presence of different HPV
genotypes.
Therefore in this study expression of MHC-I and -II was
investigated in CIN lesions of different grades and cervical
carcinomas. HPV typing was carried out by a combined
general primer-mediated (GP-) and type-specific (TS-) poly-
merase chain reaction (PCR) strategy (van den Brule et al.,
1991; Walboomers et al., 1992). In addition, HPV RNA in
situ hybridisation (RISH) was applied to some HPV 16 PCR
positive lesions, in order to localise cells containing transcrip-
tionally active HPV 16 in relation to altered MHC expres-
sion. The results indicate that MHC-I and -II alterations are
also present in CIN lesions, independent from the presence of
HPV DNA.
Materials and methods
Tissues
Tissues were obtained from patients attending the oncolog-
ical gynaecological outpatient department from the Free
University Hospital, Amsterdam, for routine diagnostic and
therapeutic procedures. Clinical material ranged from colpos-
copically directed punch biopsies to resection specimens. For-
malin fixed, paraffin embedded tissues were cut to 4 ym thick
consecutive sections for MHC expression analysis by immun-
ohistochemistry and for PCR analysis, sandwiched by two
sections for haematoxylin-eosin (HE) staining. CIN lesions
were histologically reviewed by two pathologists on both HE
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stained sections. In case of disagreement a consensus diag-
nosis was reached. CIN lesions were classified as grade I, II
or III, depending on the thickness of the epithelium involved
by dysplastic cells. Thus grade 1 CIN represents less than one
third involvement of the thickness of the epithelium, grade II
one third to two third, and grade III two third to full
thickness (Richart, 1987).
Immunohistochemistry
Paraffin embedded sections on coated slides (0.1% Poly-L-
lysine) were deparaffinised with xylene, rehydrated and endo-
genous peroxidase was blocked by incubating 30min with
methanol, containing 0.3% H202. After rinsing in PBS, sec-
tions were treated as follows for the different primary
antibodies: for Pan keratin sections were incubated with
trypsin (0.5% w/v) in 0.5% CaC12 (pH 7.8) for 30 min at 370;
for RaHC sections were treated with 0.2 M NaAc (pH 4.8)
for 15 min at RT; for LN3 sections were treated with a
saturated solution of lead thiocyanate for 2 x 5 min at 100GC.
After washing repeatedly in PBS, sections were preincubated
with normal goat (1:20) or horse (1:50) serum, depending on
the secondary antibodies used, for 20 min and incubated with
specific antibodies. The following primary antibodies were
incubated at RT for 30 min: polyclonal RaHC, 1:500, spe-
cific for HLA-A, -B and -C heavy chains (Stam et al., 1986);
monoclonal antibody (MoAb) HC10, 1:800, preferentially
recognising HLA-B and -C locus products (Stam et al.,
1986); Polyclonal Pan Keratin, 1:400, recognising a broad
spectrum of cytokeratins (Dako Patts, Glostrup, Denmark).
MoAb LN3, 1:25, recognising HLA-DR antigens (Biotech,
Breieich, FRG) was incubated overnight at 4°C.
Monoclonal antibodies (LN3, HC1O) were detected by a
biotinylated horse-anti mouse Ab 1:500 (Vector Lab, Burlin-
game, USA), polyclonals (RaHC, Polyclonal Keratin) with
biotinylated goat anti-rabbit 1:500 (Vector Lab). All secon-
dary antibodies were diluted in PBS, containing 2% (v/v)
human serum and 1% (w/v) bovine serum albumin (Sigma,
Deisenhofen, FRG). Detection was performed using horse
radish peroxidase coupled to avidin-biotin complex (Vector
Elite, Vector Lab), after which the complex was visualised
using diaminobenzidine and H202. Slides were counterstained
with haematoxylin, dehydrated and mounted in Depex.
Immunohistochemical staining was analysed independently
by two observers. In case of disagreement staining results
were re-analysed by the observers together. The percentage of
dysplastic or neoplastic cells that show staining for MHC-I
or -II was estimated, with normal epithelium and immuno-
competent cells serving as positive internal control for MHC-
I and endothelial cells and infiltrating immunocompetent cells
for MHC-II. The lesions were classified according to the
percentage of dysplastic cells that show positive or strongly
reduced to negative staining. For MHC-I expression lesions
were classifed into three categories: normal, when 75% or
more of the dysplastic cells were positively stained; hetero-
genous, when 25% to 75% of the dysplastic cells showed a
strongly reduced to negative staining; disturbed, when 75%
or more of the dysplastic cells showed strongly reduced to
negative staining. For MHC-II expression, lesions were
classified as altered, when 25% or more of the dysplastic cells
showed positive staining for MHC-II. When less than 25%
of the dysplastic cells showed positive staining, lesions were
categorised as normal.
Polymerase Chain Reaction (PCR)
Presence of HPV genotypes was analysed on tissue sections
from CIN lesions and cervical carcinomas. For HPV PCR
analysis (on tissue specimens) five 4pm thick formalin fixed,
paraffin embedded sections from each sample were
deparaffinised with xylene and washed twice with 96%
ethanol. After the tissue was centrifuged (1000g, 10 min) and
air dried, the pellet was suspended in 50plJ distilled water and
frozen at - 80°C for at least 30 min. After thawing a 50 tl
proteinase K mix (1.5 mM Mg9l2, 0.45% Tween 20 and
60pg ml ' proteinase K (Boehringer Mannheim, Mannheim,
FRG) was added and the mixture was incubated at 55°C for
several hours. Samples were then treated at 100G for 10 min
and centrifuged. Twenty ll of the supernatant was used in
the PCR reaction. The PCR was performed with general
primers (GP 5/6), recognising both sequenced and unse-
quenced HPV genotypes (Snijders et al., 1990). HPV DNA
positive samples were then subjected to type-specific PCR,
performed with primers specific for HPV 6, 11, 16, 18, 31 and
33 (van den Brule et al., 1990). Samples positive in the
general primer mediated PCR which were negative by type-
specific PCR were classified as unsequenced or unidentified
HPV genotypes (named HPV X). Cells from SiHa and Hela
cell lines, which contain HPV 16 and 18 DNA respectively,
served as positive controls for the HPV PCR. Amplification
products were analysed by 1.5% agarose gel electrophoresis
and Southern blot analysis using HPV-specific probes.
Nucleotide sequences of primers and probes used in the
PCR, as well as the conditions were published elsewhere
(Van den Brule et al., 1990; Walboomers et al., 1992). As a
negative control liver sections were cut in between the
different specimens and also subjected to PCR analysis. To
analyse the quality of target DNA for PCR purposes samples
were analysed by PCR using human ,B-globin gene specific
primers. Only P-globin PCR positive samples were included
in the study.
RNA in situ hybridisation
RNA in situ hybridisation was performed non-radioactively
on 4tm thick tissue sections as previously described by
Oudejans et al. (1989). Briefly, tissue sections on coated
(0.1% poly-L-lysine) slides were air dried overnight at 37°C
and deparaffinised by overnight incubation in xylol at 50GC.
After progressive rehydration, sections were treated with
Lugol's iodine and sodium thiosulphate, washed in phos-
phate-buffered saline, pH 7.4 (PBS), and treated subsequently
with proteinase K (0.1-1 gml-' in 50mM Tris HCG, pH
7.6, 5 mM EDTA) for 15 min at 37GC. After washing in PBS,
sections were postfixed in 4% (w/v) phosphate buffered
paraformaldehyde, pH 7.4, for 10 min at room temperature,
and washed for 5 min in PBS. Hybridisation mixture, contain-
ing 50% (v/v) deionised formamide, 2 x SSC (1 x SSC = 0.15
M NaCl, 0.015 M Na-citrate), 10% (w/v) dextran sulphate,
yeast tRNA (50 ytg ml-') (Boehringer Mannheim) and satura-
tion levels of biotinylated probe, were applied to the sections
followed by heating to 65°-70°C for 7 min. Hybridisation
was allowed to occur for 2 h at 50°C. After hybridisation,
sections were washed in 0.1 x SSC at 68°C for 60 min, and
non-specifically bound RNA-probe was removed using 0.5-1
mgml-' RNAse A (Boehringer Mannheim) in 10mM Tris
HCI, pH 8.2, 1 mM EDTA and 0.5 M NaCl for 15 min at
37°C. Sections were washed once again in 0.1 x SSC for
30min at 68°C.
The HPV-16 E7-specific probe (clone 72 kindly provided
by Dr H. Smits, Department of Virology, University of
Amsterdam) is directed against nt 622-879. An actin probe
was used as positive control probe, derived from a human
P-actin cDNA (Clontech Lab., Palo Alto, USA) and is
specific for the 5' part of the mRNA. Construction of both
probes has been described elsewhere (van den Brule et al.,
1991a). Biotinylated RNA transcripts, both sense and anti-
sense orientations, were generated using biotin-11 UTP (Sig-
ma) and SP6 or T7 RNA polymerase, following manufac-
turer's instructions (Promega, Madison, USA). RNA-probes
were precipitated with ethanol, pellets were dissolved in dis-
tilled water containing 400 units ml-' RNaseIn (Promega),
diluted in 500 yl deionised formamide containing 50fgml'
yeast tRNA (Boehringer Mannheim) and stored at - 80G.
Integrity and concentration of probes were determined by
Northern blot analysis of serial dilutions of both sense and
antisense probes. RNAs were visualised using horse radish
peroxidase coupled to avidin-biotin complex (Vector Lab)
and diaminobenzidine.
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by successive incubations with 1:500 dilution of rabbit anti-
biotin immunoglobulin (Enzo Biochemicals, Farmingdale,
USA), 1:250 dilution of biotin-labelled goat anti-rabbit
antibody (Vector Lab), both 30 min at room temperature and
I:100 dilution of colloidal gold labelled streptavidin (5 nm)
(Amersham, Buckinghamshire, UK) for 60 min at room
temperature. Sections were postfixed in phosphate buffered
glutaraldehyde (2%) for 10 min at room temperature and, to
remove chloride ions, washed extensively in water before
silver enhancement. Enhancement by the silver lactate/hydro-
quinone method was performed according to the manufactur-
er's instructions (IntenSeM system, Amersham), incubating
three times for 4min each at room temperature. Finally,
sections were counterstained with haematoxylin, dehydrated
and mounted in Depex.
RISH results were analysed using a type II confocal laser-
scan microscope with reflex contrast (Zeiss, Oberkochen,
FRG).
Statistical analysis
Statistical analysis was peformed with a chi-square test using
a BMDP statistical software program (Cork, Ireland).
Results
MHC class I and IIexpression
General antigen conservation in the sections was ascertained
with a polyclonal keratin antibody, recognizing a broad spec-
trum of cytokeratins. All specimens used in this study
showed positive staining with the pan keratin antibody.
MHC-I heavy chain expression was analysed using two
antibodies, polyclonal RaHC and monoclonal HC10. In
general, staining with HCG0 showed more clearly cell surface
localisation of the MHC-I complex on keratinocytes. How-
ever, no cases were found that showed different results in
MHC-I expression with RaHC and HC1O.
Normal epithelium, where present in the section, showed
staining for MHC-I on cells at the basal side of the epithelial
layer, as well as stromal and immunocompetent cells (Figure
la). Typical examples of dysplastic cells with positive and
disturbed expression of MHC-I are shown in Figures lb and
1c,d respectively. Disturbance of MHC-I expression was
predominantly observed at the basal side of the dysplastic
epithelium, while sometimes superficial cells still showed
positive staining (Figure Id). In Figure le and f an MHC-I
negative and a positive cervical carcinoma is shown, respec-
tively.
The number of lesions, scored as disturbed for MHC-I
expression, i.e. 75% or more of the dysplastic cells show
strongly reduced to negative staining, was 11 out of 34 CIN
I, 10 out of 32 CIN II and 12 out of 28 CIN III lesions. In
carcinomas 13 out of 27 cases were scored as disturbed.
Heterogeneity of MHC-I expression, i.e. 25 to 75% of the
dysplastic cells show strongly reduced to negative staining,
was scored in 12 out of 34 CIN I, 15 out of 32 CIN II and
12 out of 28 CIN III lesions. In carcinomas 9 out of 27 cases
were scored as heterogenous.
MHC-II expression was determined using LN3, staining
HLA-DR locus products. In normal epithelium only a few
immunocompetent cells are stained (Figure 2a). Examples of
negative (Figure 2b) and upregulated (Figure 2c,d) expression
of MHC-II on dysplastic epithelial cells are shown. Cell
surface localisation of the MHC-II antigens could sometimes
be observed (Figure 2d), although other lesions showed a
more diffuse cytoplasmic staining for MHC-II (Figure 2c).
The expression pattern of MHC-II in CIN lesions was differ-
ent from MHC-I. Altered class II expression could occas-
ionally be observed on superficial cells, while basal and
parabasal cells did not show upregulated MHC-II expression
(Figure 2c). In Figure 2e and f carcinomas with no and
upregulated MHC-II expression are shown, respectively.
The number of lesions, scored as altered for MHC-II, i.e.
25% or more of the dysplastic cells show staining, was 12 out
of 34 CIN I, 20 out of 32 CIN II and 17 out of 28 CIN III
lesions. In carcinomas 14 out of 24 were scored for altered
MHC-II expression.
MHC-I and -II expression results per CIN group and for
the carcinomas are summarised in Table I. Statistical analysis
of these data revealed no significant differences (P-value
>0.01) in MHC alterations between the different CIN grades
and carcinomas.
Taking the CIN lesions and carcinomas together 48 out of
121 samples showed simultaneous changes of MHC-I and -II
expression. An additional 59 samples showed changes of one
class while the other was normal. The remaining 14 samples
showed normal expression of both classes. Since this distribu-
tion is not statistically significant (P>0.01) it is concluded
that there is no correlation between changes in MHC-I and
-II expression.
HPVgenotypes in CIN lesions and cervical carcinomas
HPV prevalence rates in the different CIN grades and car-
cinomas are illustrated in Figure 3. An increase of HPV
prevalence was associated with an increase of the severity of
the lesion. In CIN I, CIN II and CIN III/cervical carcinomas
an HPV prevalence of 68%, 91% and 100% was found,
respectively. Also the contribution of the HPV types assoc-
iated with cervical carcinoma (type 16, 18 and 31) increased
from 53% in CIN I, 75% in CIN II to 96% in CIN III and
100% in cervical carcinomas. Other HPV types, i.e. HPV 6
and HPV X, were found only in CIN I and II (n = 11),
whereas in none of the samples HPV 11 or 33 could be
detected.
Association between presence ofHPVgenotype and MHC
alterations
All three MHC-I expression patterns (i.e. normal, hetero-
genous and altered) were observed in lesions, positive for
'high-risk' HPV types 16, 18 or 31. Also in lesions, positive
for HPV 6, X or negative for any HPV genotype, all three
MHC patterns could be found. Using statistical analysis no
significant differences in MHC-I expression patterns could be
established between the different HPV containing and the
HPV negative lesions (P-value>0.01).
Both normal and upregulated MHC-II expression was
observed on dysplastic cells of lesions, positive for 'high-risk'
HPV types, as well as in lesions, positive for HPV 6, X or
negative for any HPV genotype. No significant differences in
MHC-II expression could be established by statistical analy-
sis between the different HPV containing and HPV negative
lesions (P-value>0.01). The results are summarised in Table
II.
To find out whether HPV, if present, is localised in the
same dysplastic cells from which MHC status was deter-
mined, additional RNA in situ hybridisation (RISH) was
performed on consecutive sections, using an E7-specific RNA
probe. Several PCR HPV 16 DNA positive CIN lesions and
cervical carcinomas were analysed with RISH, and two
typical examples of CIN lesions are shown in Figure 4. An
MHC-I positive CIN II lesion is shown with membranous
staining of dysplastic cells at the basal side of the epithelial
layer (Figure 4a). RISH reveals presence of HPV 16-E7
transcripts in the same area, with signals restricted to the
dysplastic cells (Figure 4b). In Figure 4c and d a detail of a
CIN I lesion is shown with heterogenous staining for MHC-I
heavy chains in the dysplastic cells. Also in this dysplastic
area HPV 16-E7 mRNAs can be detected (Figure 4d). The
E7 sense RNA-probe was used as a negative control and
gave no signal (not shown). Also in nine carcinomas, des-
cribed earlier (van de Brule et al., 1991a), HPV 16 E7
transcripts were found in all carcinoma cells. In these sam-
ples both normal and altered MHC-I and -II expression
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Figure 1 MHC class I expression (MHC-I) in normal epithelium a, CIN lesions b-d, and cervical carcinomas e, f, as shown by
MoAb HCIO, directed against HLA-B and -C locus products. Size bars represent 50 im. a, Normal squamous epithelium of the
uterine cervix, showing staining of basal and parabasal cells. b, Grade III CIN lesion, showing staining of all atypical cells in the
full thickness of the epithelium. c, CIN II lesion showing staining of the lower half of the surface epithelium. Note that MHC-I
expression in the atypical metaplastic cells of the endocervical tube is absent. d, CIN III lesion with only the upper third of the
epithelium staining for MHC-I. Note the staining of the mononuclear cells in the stroma. e and f, representative cervical
carcinomas without e, and with f, staining for MHC-I, whereas mononuclear cells in both tissues do stain for MHC-I (positive
control).
Discussion
The development of malignant tumours can be regarded as
an example of cells escaping immune surveillance. One possi-
ble mechanism is down-regulation of MHC-I expression,
affecting recognition and clearance by tumour specific CTLs.
MHC-I alterations have been found in several human malig-
nancies such as colon cancer (McDougall et al., 1990), Bur-
kitt lymphomas (Andersson et al., 1991), small cell lung
cancer (Doyle et' al., 1985), breast cancer (Fleming et al.,
1981) and melanomas (Brocker et al., 1985). Also in cervical
carcinomas this phenomenon has been observed in a substan-
tial number of the carcinomas examined (Connor & Stern,
1990). However, the role of this phenomenon in the develop-
ment of these malignancies is as yet unclear.
In this study formalin fixed, paraffin embedded material ofa
c
e f
Figure 2 MHC class II (MHC-II) expression in normal cervical epithelium a, CIN lesions b-d, and in cervical carcinomas e, f, as
shown by MoAb LN3, specific for HLA-DR locus products. Size bars represent 501tm. a, Normal squamous epithelial cells of the
uterine cervix lack MHC-II. Weak staining of dendritic cells in the epithelial layer and mononuclear cells in the stroma. b, CIN III
lesion. Most of the atypical cells do not stain for MHC-II, whereas mononuclear cells in the stroma do stain. c, CIN III lesion,
showing heterogenous, diffuse staining for MHC-II on superficial atypical cells. Basal layers show no or very weak staining. d, CIN
II lesion, in which cell surface expression of MHC-II on atypical epithelial cells can be seen. e and f, Cervical carcinomas showing
no e, and strong f, staining for MHC-II, whereas mononuclear cells in the stroma do show MHC-II expression.
94 CIN lesions of different grades and 27 cervical carcinomas
was analysed for MHC-I expression by immunohistochemis-
try using class I heavy chain specific antibodies HCIO and
RaHC. In a substantial number of CIN lesions and car-
cinomas dysplastic cells showed a strongly reduced or even
negative staining for MHC-I antigens, whereas normal epi-
thelial cells and immunocompetent cells in the same sections
were positive for MHC-I. This indicates that the observed
alterations in MHC-I expression are related to dysplastic
changes. This is also substantiated by the lack of MHC-I
alterations in six normal cervical tissues of women undergo-
ing hysterectomy for benign disease of the uterus such as
leiomyoma and prolapse. Both the monoclonal HCIO anti-
body and polyclonal RaHC showed similar results, which
indicates that not one epitope is affected, but rather the
amount of intact wild type heavy chain polypeptides is
1376 F.V. CROMME et al.
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Figure 3 Total HPV prevalence and HPV 16/18/31 prevalence in CIN lesions and squamous cell carcinomas
was detected and genotyped by a combined general primer-mediated and type specific PCR strategy.
(SCC). HPV DNA
Table I MHC class I (MHC-I) and II (MHC-I1) expression patterns in CIN I to III lesions and squamous cell carcinomas (SCC)
Cervical lesion
Group 1 Group 2 Group 3 Group 4
CIN I (n = 34) CIN II (n = 32) CIN III (n = 28) SCC (n = 27)a P-value betwveen
MHC-I normal 11 7 4 5 group I vs group 3: 0.09
disturbed 11 10 12 13 group 1 vs group 4: 0.21
heterogenous 12 15 12 9 group I vs group 4: 0.29
MHC-II normal 22 12 11 10 group 1 vs group 2: 0.03
altered 12 20 17 14 group 1 vs group 2: 0.03
The lowest P-values between the different groups are given for each MHC expression pattern. P-values below 0.01 (P<0.01) by Chi-square
test is regarded to indicate a significant difference. dOnly 24 samples were examined for MHC class II.
Table 11 MHC class I (MHC-1) and II (MHC-II) expression patterns for lesions, positive for HPV 16/18/31, positive
for HPV 6/X and negative for any HPV type as determined by PCR
HPV status
Group 1 Group 2 Group 3
HPV 16118131 (n = 96)0 HPV 6/X (n = 11) HPV neg. (n = 14) P-value betwi,een
MHC-I normal 18 3 6 group 1 vs group 3: 0.04
disturbed 37 5 4 group 2 vs group 3: 0.38
heterogenous 41 3 4 group 1 vs group 3: 0.31
MHC-II normal 40 6 9 group 1 vs group 3: 0.14
altered 53 5 5 group 1 vs group 3: 0.14
The lowest P-values between the different groups are given for each MHC expression pattern. P-values below 0.01
(P<0.01) by Chi-square test is regarded to indicate a significant difference. 4Only 93 samples were examined for
MHC class II.
reduced or alternatively large modifications have taken place
affecting the recognition by both antibodies.
The percentage of MHC-I downregulation (heterogenous
and disturbed patterns) in carcinomas in our study (77%) is
comparable with the percentage of complete and allele-
specific down-regulation taken together in the carcinoma
group studied by Connor & Stern (1990). However, when
only analysing complete loss of MHC-I expression the per-
centage of carcinomas showing MHC-I alterations observed
using HCIO and RaHC (48%) was considerably higher than
obtained with W6/32 (9%) by Connor & Stern (1990). The
monoclonal antibody W6/32 recognises MHC-I heavy chains,
complexed with P2-microglobulin, and is reactive only on
frozen tissue, whereas HCIO and RaHC used in our study
recognise MHC-I heavy chain antigens both in frozen and
paraffin embedded tissue (Stam et al., 1990). This implicates
that the reduced staining for MHC-I heavy chains observed
in our study cannot be caused by formalin fixation. One
possible explanation for the different MHC-1 staining pat-
terns could be the presence of incomplete or modified heavy
chains, which stain positive with W6/32, but lack the epitopes
recognised by HCIO/RaHC. Another possibility might be a
difference in staining sensitivity between W6/32 and HCIO/
RaHC. In this case allele-specific down-regulation, leading to
reduced steady state levels of MHC-I heavy chains, could
result in the loss of staining with HCIO/RaHC, while W6/32
staining is positive. Thus the negative staining with HC1O
and RaHC in CIN lesions and cervical carcinomas, as
observed in this study, can be based on total down-regulation
of MHC-I as well as large modifications of the heavy chains.
Also allele-specific down-regulation of MHC-I cannot be
excluded.
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Figure 4 Immunohistochemical analysis of MHC-I expression and RNA in situ hybridisation (RISH) with an HPV 16 E7-specific
probe, performed on consecutive tissue sections of a CIN II (panels a, b) and CIN I (panels c, d) lesion. a, Immunohistochemical
staining of CIN II section using HClO monoclonal antibody. Basal and parabasal cells are stained, with the signal localised on the
cell membrane. b, Reflection signal of antisense HPV 16-E7 probe, obtained by confocal laserscan microscopy. Signal (white dots)
is restricted to dysplastic epithelial cells, while stroma cells show background levels of signal. c, Detail of a CIN I lesion
heterogenously stained with HC1O monoclonal antibody. d, RISH shows HPV 16-E7 transcripts in both dysplastic areas that show
reduced staining for MHC-I and in areas that are positively stained for MHC-I. Size bars represent 30 jAm.
Changes in MHC-II expression were detected as well in a
substantial number of CIN lesions and cervical carcinomas.
MHC-II upregulation on epithelial cells could enhance
tumor-specific immunity by bypassing the classical antigen
presenting cell (APC) mediated route and directly presenting
antigen in the context of MHC-II to T-helper cells (Ostrand-
Rosenberg et al., 1991). This would result in a shorter and
faster pathway of local lymphokine production, giving help
to CTL-mediated killing and possibly also to other cells like
natural killer cells. This could explain the favourable prog-
nosis of tumours expressing MHC-II antigens (Esteban et al.,
1990; Gutierrez et al., 1987). However, upregulation of
MHC-II expression in melanoma is reported to be associated
with a shorter disease-free survival (Ruiter et al., 1986),
indicating that de novo MHC-II expression on malignant
cells does not always indicate a favourable prognosis.
Upregulation of MHC-II has been reported in cervical car-
cinomas (Ferguson et al., 1985; Glew et al., 1992) and in
CIN lesions (Warhol et al., 1989). Our results show no
significant differences in MHC-II expression between
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different groups of CIN and cervical carcionomas, suggesting
that upregulated MHC-II expression does not supply help to
a possible cytotoxic response against premalignant cervical
lesions.
A number of lesions in this study showed alterations of
both MHC classes, while other lesions exhibited normal
MHC-I expression with altered MHC-II expression, and vice
versa. Apparently, alteration of one MHC class is not exclus-
ively correlated with alteration of the other. Thus different
mechanisms may be involved in the regulation of MHC
expression of both classes. It seems that a scale of different
MHC-I and -II expression patterns can be observed in CIN
lesions and cervical carcinomas indicating that local
differences may exist in the cellular immune response to HPV
induced premalignant and malignant cervical lesions.
Aberrant MHC-I expression could be observed in HPV
negative lesions, as well as lesions containing high-risk HPVs
(i.e. HPV 16, 18 and 31) and HPV types 6 or X, as deter-
mined by PCR. Normal MHC-I expression patterns were
also found in all these groups. This indicates that variations
of MHC-I expression are not directly correlated with the
presence of specific HPV genotypes. Also no correlation
could be found between MHC-II expression and presence of
any of the HPV types either, which suggests that the process
of upregulation of MHC-II is not related to the presence of
HPV DNA. This is in agreement with the observation on
cervical carcinomas by Connor & Stern (1990) and Glew et
al. (1992), using Southern blot analysis for HPV typing.
Since the PCR, performed on cell extracts, cannot supply
morphological information on HPV distribution additional in
situ hybridisation was carried out to establish that changes in
MHC expression and HPV presence were localised in the
same dysplastic/neoplastic cells. For optimal sensitivity of
HPV detection RNA instead of DNA in situ hybridisation
was performed, because with the latter method low copy
numbers of HPV genotypes might not be detected (Wal-
boomers et al., 1988). The HPV 16-E7 RNA probe was used
for this purpose since this gene is highly expressed in HPV
transformed cells and E7 transcripts can be detected in all
neoplastic cells of HPV 16 containing cervical carcinomas
(van den Brule et al., 1991a). Results showed that E7 trans-
cripts were found in cells with normal as well as in cells with
changes in MHC expression in CIN lesions and carcinomas.
This indicates that presence of E7 transcripts alone does not
result in altered MHC expression. Further transcriptional
analysis is necessary to reveal whether other HPV encoded
proteins play a role in aberrant expression of MHC-I or -II.
Since the expression of several early and all late HPV genes
can be influenced by HPV DNA integration, also the HPV
physical state could be an important factor and needs to be
further analysed.
Recently we have investigated HPV 16 E7 transcriptionally
active cervical carcinomas (van den Brule et al., 1991a), which
show a disturbed MHC-I expression using RISH with heavy
chain locus-specific antisense RNA probes. All carcinomas,
that show MHC-I downregulation as detected with HC10,
showed abundant MHC-I heavy chain transcripts in car-
cinoma cells. This indicates that down-regulation occurs at
the post-transcriptional level (Walboomers et al., abstract PV
workshop Seattle 1991, manuscript in preparation). Similar
studies have to be performed for MHC-II expression using
RISH, to establish if upregulated MHC-II expression occurs
at the transcriptional or post-transcriptional level.
Finally, it has also to be taken into consideration that the
biological behaviour of CIN lesions is very heterogenous and
cannot be predicted by a single histological observation. In
general it is assumed that only a minority of CIN lesions
show progression to invasive cancer (Richart, 1987). This
means that from randomly taken CIN lesions only a small
percentage (approximately 10%) represent progressive CIN.
Therefore it seems important to define the clinical parameters
of the study groups when MHC expression levels in CIN
lesions are compared with results obtained by others. CIN
lesions analysed in this study originated from a selected
group of women attending the oncological gynaecological
clinic, having a high recurrency rate of CIN and are more
prone to develop cervical cancer. Currently, this study is
extended with CIN lesions of patients that could be ret-
rospectively (Gaarenstroom et al., submitted) and prospec-
tively defined on clinical behaviour. Patients, exhibiting
regressive, progressive or persistent CIN disease will be
analysed for MHC expression and presence of HPV geno-
types. These data will give information about the biological
significance of disturbed MHC-I expression, as detected by
HCGO and RaHC, as well as W6/32.
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